newsfilter
← Latest News
GlobeNewswire·

Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis

Biosimilar Jubbonti® approved for all indications of Prolia* reference medicine.Sandoz continues to expand access for patients in Canada, offering denosumab biosimilar to treat osteoporosis and increase bone